Skip to main content
CRBP logo

Corbus Pharmaceuticals Holdings, Inc.

CRBPNASDAQHealthcareBiotechnology

$4.52Today:- (-)1Y −77.59%

As of Oct 16, 2026 close

Market cap
$84.04M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$4.37$20.56
Volume (live)
-
Avg. volume (3M)
1.26M

Corbus Pharmaceuticals Holdings (CRBP) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Corbus Pharmaceuticals Holdings had return on equity of -54.2% (up from -59.3%), debt-to-equity of 0.01 (down from 0.02), a current ratio of 8.07 (down from 12.94) and return on assets of -32.9% (up from -33.1%). A current ratio of 8.07 means current assets exceed current liabilities.

Corbus Pharmaceuticals Holdings Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio----87.4526.68
P/B Ratio1.021.01-3.870.421.122.32
Price/Tangible Book1.021.01-0.421.122.32
Enterprise Value Ratios
EV/Revenue-----12.54
Profitability & Returns
Return on Equity (ROE)-54.18%-59.34%-341.99%-82.95%-79.80%-432.68%
Return on Assets (ROA)-32.90%-33.07%-59.57%-25.02%-33.32%-101.37%
Return on Capital Employed (ROCE)-57.80%-33.80%1244.60%-64.90%-61.70%-174.50%
Leverage & Solvency Ratios
Debt/Equity0.010.02-3.020.760.390.59
Liquidity Ratios
Current Ratio8.0712.940.744.765.892.89
Quick Ratio7.9612.610.664.685.742.76
Efficiency Ratios
Asset Turnover----0.010.05
Yield & Distribution Ratios
Earnings Yield-52.07%-27.98%-166.94%-305.90%-59.19%-105.92%
FCF Yield-42.76%-29.08%-135.11%-271.30%-62.56%-95.36%
Buyback Yield-22.00%-152.23%-3.76%-1.85%-57.23%-22.28%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Corbus Pharmaceuticals Holdings Financial Ratios

What is Corbus Pharmaceuticals Holdings's return on equity?

Corbus Pharmaceuticals Holdings's return on equity (ROE) was -54.2% for fiscal 2025 (period ended Dec 31, 2025). It was -59.3% a year earlier.

What is Corbus Pharmaceuticals Holdings's debt-to-equity ratio?

Corbus Pharmaceuticals Holdings's debt-to-equity ratio was 0.01 for fiscal 2025 (period ended Dec 31, 2025). It was 0.02 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition